Haematologica (May 2017)
Improved survival after acute graft-versus-host disease diagnosis in the modern era
- Hanna J. Khoury,
- Tao Wang,
- Michael T. Hemmer,
- Daniel Couriel,
- Amin Alousi,
- Corey Cutler,
- Mahmoud Aljurf,
- Joseph H. Antin,
- Mouhab Ayas,
- Minoo Battiwalla,
- Jean-Yves Cahn,
- Mitchell Cairo,
- Yi-Bin Chen,
- Robert Peter Gale,
- Shahrukh Hashmi,
- Robert J. Hayashi,
- Madan Jagasia,
- Mark Juckett,
- Rammurti T. Kamble,
- Mohamed Kharfan-Dabaja,
- Mark Litzow,
- Navneet Majhail,
- Alan Miller,
- Taiga Nishihori,
- Muna Qayed,
- Helene Schoemans,
- Harry C. Schouten,
- Gerard Socie,
- Jan Storek,
- Leo Verdonck,
- Ravi Vij,
- William A. Wood,
- Lolie Yu,
- Rodrigo Martino,
- Matthew Carabasi,
- Christopher Dandoy,
- Usama Gergis,
- Peiman Hematti,
- Melham Solh,
- Kareem Jamani,
- Leslie Lehmann,
- Bipin Savani,
- Kirk R. Schultz,
- Baldeep M. Wirk,
- Stephen Spellman,
- Mukta Arora,
- Joseph Pidala
Affiliations
- Hanna J. Khoury
- Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA
- Tao Wang
- CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA;Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, WI, USA
- Michael T. Hemmer
- CIBMTR (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA
- Daniel Couriel
- Utah Blood and Marrow Transplant Program-Adults, Salt Lake City, UT, USA
- Amin Alousi
- Department of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Corey Cutler
- Center for Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
- Mahmoud Aljurf
- Department of Pediatric Hematology Oncology, King Faisal Specialist Hospital Center & Research, Riyadh, Saudi Arabia
- Joseph H. Antin
- Center for Hematologic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
- Mouhab Ayas
- Department of Pediatric Hematology Oncology, King Faisal Specialist Hospital Center & Research, Riyadh, Saudi Arabia
- Minoo Battiwalla
- Hematology Branch, National Heart, Lung and Blood Institute-NIH, Bethesda, MD, USA
- Jean-Yves Cahn
- Department of Hematology, University Hospital, Grenoble, France
- Mitchell Cairo
- Division of Pediatric Hematology, Oncology and Stem Cell Transplantation, Department of Pediatrics, New York Medical College, Valhalla, NY, USA
- Yi-Bin Chen
- Division of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USA
- Robert Peter Gale
- Hematology Research Centre, Division of Experimental Medicine, Department of Medicine, Imperial College London, UK
- Shahrukh Hashmi
- Department of Internal Medicine, Mayo Clinic Rochester, MN, USA;Department of Oncology, King Faisal Specialist Hospital Center & Research, Riyadh, Saudi Arabia
- Robert J. Hayashi
- Division of Pediatric Hematology/Oncology, Department of Pediatrics, Washington University School of Medicine in St. Louis, MO, USA
- Madan Jagasia
- Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN, USA
- Mark Juckett
- Division of Hematology/Oncology/Bone Marrow Transplantation, Department of Medicine, University of Wisconsin Hospital and Clinics, Madison, WI, USA
- Rammurti T. Kamble
- Division of Hematology and Oncology, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA
- Mohamed Kharfan-Dabaja
- Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
- Mark Litzow
- Department of Internal Medicine, Mayo Clinic Rochester, MN, USA
- Navneet Majhail
- Blood & Marrow Transplant Program, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA
- Alan Miller
- Division of Hematology and Oncology, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA
- Taiga Nishihori
- Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
- Muna Qayed
- Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA
- Helene Schoemans
- University Hospital of Leuven, Belgium
- Harry C. Schouten
- Department of Hematology, Academische Ziekenhuis, Maastricht, the Netherlands
- Gerard Socie
- Department of Hematology, Hopital Saint Louis, Paris, France
- Jan Storek
- Department of Medicine, University of Calgary, AB, Canada
- Leo Verdonck
- Isala Clinics Zwolle, the Netherlands
- Ravi Vij
- Division of Hematology and Oncology, Washington University School of Medicine, St. Louis, MO, USA
- William A. Wood
- Division of Hematology/Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC, USA
- Lolie Yu
- Division of Hematology/Oncology & HSCT, The Center for Cancer and Blood Disorders, Children’s Hospital/Louisiana State University Medical Center, New Orleans, LA, USA
- Rodrigo Martino
- Division of Clinical Hematology, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain
- Matthew Carabasi
- Thomas Jefferson University Hospital, Philadelphia, PA, USA
- Christopher Dandoy
- Cincinnati Children’s Hospital Medical Center, OH, USA
- Usama Gergis
- Hematologic Malignancies & Bone Marrow Transplant, Department of Medical Oncology, New York Presbyterian Hospital/Weill Cornell Medical Center, NY, USA
- Peiman Hematti
- Division of Hematology/Oncology/Bone Marrow Transplantation, Department of Medicine, University of Wisconsin Hospital and Clinics, Madison, WI, USA
- Melham Solh
- The Blood and Marrow Transplant Group of Georgia, Northside Hospital, Atlanta, GA, USA
- Kareem Jamani
- Department of Medicine, University of Calgary, AB, Canada
- Leslie Lehmann
- Dana Farber Cancer Institute/Boston Children’s Hospital, MA, USA
- Bipin Savani
- Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN, USA
- Kirk R. Schultz
- Department of Pediatric Hematology, Oncology and Bone Marrow Transplant, British Columbia’s Children’s Hospital, The University of British Columbia, Vancouver, BC, Canada
- Baldeep M. Wirk
- Division of Bone Marrow Transplant, Seattle Cancer Care Alliance, WA, USA
- Stephen Spellman
- CIBMTR (Center for International Blood and Marrow Transplant Research), National Marrow Donor Program/Be the Match, Minneapolis, MN, USA
- Mukta Arora
- Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota Medical Center, Minneapolis, MN, USA
- Joseph Pidala
- Department of Blood and Marrow Transplantation, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
- DOI
- https://doi.org/10.3324/haematol.2016.156356
- Journal volume & issue
-
Vol. 102,
no. 5
Abstract
A cute graft-versus-host disease remains a major threat to a successful outcome after allogeneic hematopoietic cell transplantation. While improvements in treatment and supportive care have occurred, it is unknown whether these advances have resulted in improved outcome specifically among those diagnosed with acute graft-versus-host disease. We examined outcome following diagnosis of grade II-IV acute graft-versus-host disease according to time period, and explored effects according to original graft-versus-host disease prophylaxis regimen and maximum overall grade of acute graft-versus-host disease. Between 1999 and 2012, 2,905 patients with acute myeloid leukemia (56%), acute lymphoblastic leukemia (30%) or myelodysplastic syndromes (14%) received a sibling (24%) or unrelated donor (76%) blood (66%) or marrow (34%) transplant and developed grade II-IV acute graft-versus-host disease (n=497 for 1999–2001, n=962 for 2002–2005, n=1,446 for 2006–2010). The median (range) follow-up was 144 (4–174), 97 (4–147) and 60 (8–99) months for 1999–2001, 2002–2005, and 2006–2010, respectively. Among the cohort with grade II-IV acute graft-versus-host disease, there was a decrease in the proportion of grade III-IV disease over time with 56%, 47%, and 37% for 1999–2001, 2002–2005, and 2006–2012, respectively (P